Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-23T03:47:45.439Z Has data issue: false hasContentIssue false

Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection – CORRIGENDUM

Published online by Cambridge University Press:  25 November 2022

Md S. Bhuiyan
Affiliation:
Division of Infectious Disease, University of Utah School of Medicine, Salt Lake City, UT, USA
Ben J. Brintz
Affiliation:
Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA
Alana L. Whitcombe
Affiliation:
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Maurice Wilkins Center, University of Auckland, Auckland, New Zealand
Alena J. Markmann
Affiliation:
Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Luther A. Bartelt
Affiliation:
Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Nicole J. Moreland
Affiliation:
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Maurice Wilkins Center, University of Auckland, Auckland, New Zealand
Andrew S. Azman
Affiliation:
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA Faculty of Medicine, Institute of Global Health, University of Geneva, Geneva, Switzerland
Daniel T. Leung
Affiliation:
Division of Infectious Disease, University of Utah School of Medicine, Salt Lake City, UT, USA Divsion of Microbiology & Immunology, University of Utah School of Medicine, Salt Lake City, UT, USA
Rights & Permissions [Opens in a new window]

Abstract

Type
Corrigendum
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

The original article was published with an incorrect funding acknowledgement.

Currently, the funding statement reads,

This work was supported in part by the National Institutes of Health (R01 AI135115 to D. T. L.), with funding in part from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health, through Grant UL1TR002538 (formerly 5UL1TR001067-05, 8UL1TR000105 and UL1RR025764), and from the SeroNet programme of the National Cancer Institute (1U01CA261277-01) and the NIH SeroNet Serocenter of Excellence Award (U54 CA260543).

It should read:

This work was supported in part by the National Institutes of Health (R01 AI135115 to D. T. L.), with funding in part from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health, through Grant UL1TR002538 (formerly 5UL1TR001067-05, 8UL1TR000105 and UL1RR025764), and the NIH SeroNet Serocenter of Excellence Award (U54 CA260543).

This has now been updated in the original article.

References

Bhuiyan, M, Brintz, B, Whitcombe, A, Markmann, A, Bartelt, L, Moreland, N, . . . Leung, D (2022). Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection. Epidemiology and Infection, 150, E20. doi:10.1017/S0950268821002764CrossRefGoogle ScholarPubMed